BCMAS EXAM AND STUDY GUIDE NEWEST 2026 TEST
BANK| COMPLETE 650 REAL EXAM QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+| BCMAS FINAL EXAM PREP
2026 (BRAND NEW!!)
1. What is the primary purpose of an Investigational New
Drug (IND) application?
A. To market a new drug
B. To obtain permission to ship an investigational drug across
state lines for clinical trials
C. To report adverse events to the FDA
D. To renew a drug patent
Answer: B – To obtain permission to ship an investigational
drug across state lines for clinical trials
Rationale: An IND is filed with the FDA to obtain an exemption
from the Federal Food, Drug, and Cosmetic Act, allowing the
1
,sponsor to lawfully ship an investigational drug for human use in
clinical trials.
2. Which phase of a clinical trial primarily assesses safety and
tolerability in a small number of healthy volunteers or
patients (20–80 subjects)?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: A – Phase I
Rationale: Phase I trials are first-in-human studies focused on
safety, tolerability, pharmacokinetics, and pharmacodynamics.
Phase II assesses efficacy and dose-ranging; Phase III is large-scale
confirmatory efficacy; Phase IV is post-marketing surveillance.
3. What does “IND” stand for in drug development?
A. Investigational New Drug
2
,B. International New Drug
C. Investigational Nonclinical Drug
D. Immediate New Drug
Answer: A – Investigational New Drug
Rationale: The IND application is the mechanism by which a sponsor
obtains FDA authorization to begin human clinical trials after
completing preclinical studies.
4. Which type of FDA application is submitted for approval to
market a new drug in the United States?
A. IND
B. ANDA
C. NDA (New Drug Application) or BLA (Biologics License
Application)
D. IDE
Answer: C – NDA (New Drug Application) or BLA (Biologics
License Application)
3
, Rationale: An NDA is for small molecule drugs; a BLA is for
mn mn mn mn mn mn mn mn mn mn mn
mn biologics (monoclonal antibodies, gene therapies, etc.). Both
mn mn mn mn mn mn
mn request FDA approval for marketing.
mn mn mn mn
5. An Abbreviated New Drug Application (ANDA) is used for:
mn mn mn mn mn mn mn mn
A. New molecular entities
mn mn
B. Generic drugs that are bioequivalent to a reference listed
mn mn mn mn mn mn mn mn
mn drug
C. Biologics
D. Over-the-counter (OTC) monograph products mn mn mn
Answer: B – Generic drugs that are bioequivalent to a reference
mn mn mn mn mn mn mn mn mn mn
mn listed drug
mn
Rationale: The ANDA pathway allows generic drug approval without
mn mn mn mn mn mn mn mn
mn repeating clinical trials, provided bioequivalence is demonstrated
mn mn mn mn mn mn
mn and no new patents/ exclusivities block entry.
mn mn mn mn mn mn
6. The “PHS Act” section 351(a) and (k) apply to:
mn mn mn mn mn mn mn mn
A. Small molecules mn
4
BANK| COMPLETE 650 REAL EXAM QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+| BCMAS FINAL EXAM PREP
2026 (BRAND NEW!!)
1. What is the primary purpose of an Investigational New
Drug (IND) application?
A. To market a new drug
B. To obtain permission to ship an investigational drug across
state lines for clinical trials
C. To report adverse events to the FDA
D. To renew a drug patent
Answer: B – To obtain permission to ship an investigational
drug across state lines for clinical trials
Rationale: An IND is filed with the FDA to obtain an exemption
from the Federal Food, Drug, and Cosmetic Act, allowing the
1
,sponsor to lawfully ship an investigational drug for human use in
clinical trials.
2. Which phase of a clinical trial primarily assesses safety and
tolerability in a small number of healthy volunteers or
patients (20–80 subjects)?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: A – Phase I
Rationale: Phase I trials are first-in-human studies focused on
safety, tolerability, pharmacokinetics, and pharmacodynamics.
Phase II assesses efficacy and dose-ranging; Phase III is large-scale
confirmatory efficacy; Phase IV is post-marketing surveillance.
3. What does “IND” stand for in drug development?
A. Investigational New Drug
2
,B. International New Drug
C. Investigational Nonclinical Drug
D. Immediate New Drug
Answer: A – Investigational New Drug
Rationale: The IND application is the mechanism by which a sponsor
obtains FDA authorization to begin human clinical trials after
completing preclinical studies.
4. Which type of FDA application is submitted for approval to
market a new drug in the United States?
A. IND
B. ANDA
C. NDA (New Drug Application) or BLA (Biologics License
Application)
D. IDE
Answer: C – NDA (New Drug Application) or BLA (Biologics
License Application)
3
, Rationale: An NDA is for small molecule drugs; a BLA is for
mn mn mn mn mn mn mn mn mn mn mn
mn biologics (monoclonal antibodies, gene therapies, etc.). Both
mn mn mn mn mn mn
mn request FDA approval for marketing.
mn mn mn mn
5. An Abbreviated New Drug Application (ANDA) is used for:
mn mn mn mn mn mn mn mn
A. New molecular entities
mn mn
B. Generic drugs that are bioequivalent to a reference listed
mn mn mn mn mn mn mn mn
mn drug
C. Biologics
D. Over-the-counter (OTC) monograph products mn mn mn
Answer: B – Generic drugs that are bioequivalent to a reference
mn mn mn mn mn mn mn mn mn mn
mn listed drug
mn
Rationale: The ANDA pathway allows generic drug approval without
mn mn mn mn mn mn mn mn
mn repeating clinical trials, provided bioequivalence is demonstrated
mn mn mn mn mn mn
mn and no new patents/ exclusivities block entry.
mn mn mn mn mn mn
6. The “PHS Act” section 351(a) and (k) apply to:
mn mn mn mn mn mn mn mn
A. Small molecules mn
4
